Global Campaign for Microbicides

Home

Home » About Microbicides » Testing & Trials » Trial Results » CAPRISA 004: Tenofovir Gel

CAPRISA 004: Tenofovir Gel

Microbicide Trial Lifts Hope for Women’s HIV Prevention

CAPRISA 004 trial shows moderate protection against transmission of virus

 

Contact:

Melissa May, Communications Director

Global Campaign for Microbicides

mmay@path.org

+ 1-202-412-9361

 

Johannesburg, South Africa, and Washington, DC, 20 July 2010—Results of an advanced  clinical trial of an antiretroviral-based microbicide candidate were announced at the International AIDS Conference in Vienna, Austria.  The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.

 

GCM Press Release on CAPRISA 004 – 19  July 2010

 

Telebriefing for Advocates to Discuss Results of the

CAPRISA 004 Microbicide Trial

 

On Wednesday, 21 July 2010, the Global Campaign for Microbicides hosted a tele-briefing for advocates to discuss the findings of the CAPRISA 004 trial. We were joined by over 180 advocates and others from the field to learn more about and discuss these pivotal trial results. 

 

A heartfelt thanks goes to Professor Salim Abdool Karim for presenting on the results of the CAPRISA 004 trial in this forum for advocates. 

 

We would like to thank all the speakers who offered their expertise during the tele-briefing.

 

Speakers included: 

  • Prof Salim Abdool Karim, Director of CAPRISA and Co-Principal Investigator of CAPRISA 004, South Africa
  • Dr Gina Brown, Coordinator, Microbicides and Women and Girls Research, Office of AIDS Research, National Institutes of Health, USA
  • Dr Samu Dube, Director of Africa Programmes, Global Campaign for Microbicides, South Africa
  • Dr Henry Gabelnick, Executive Director, CONRAD, USA
  • Dr Emmanuel Njeuhmeli, Senior Biomedical Prevention Advisor, USAID, USA
  • Dr Jim Rooney, Vice President Medical Affairs, Gilead Sciences, Inc., USA
  • Emily Bass, Program Director, AVAC, USA
  • Yasmin Halima, Director, Global Campaign for Microbicides, USA, chair and moderator of an interactive discussion with participants

The call aimed to: 

 

     1.  Share results from the CAPRISA 004 microbicide trial;

     2.  Provide opportunities to ask investigators, researchers,

          product developers, and advocates questions about the study

          design, findings, and implications of the results;

     3.  Discuss next steps for microbicide and other biomedical 

          prevention research including oral pre-exposure prophylaxis

          (PrEP).

 

Listen to the recording here

 

Download the presentation here

 

See the webcast of the GCM-sponsored satellite meeting titled Using Antiretrovirals to Prevent HIV: Implications of the outcome of the CAPRISA 004 tenofovir-gel microbicide trial    Please click here

 

Visit the AIDS2010 Resources Page for CAPRISA Trial here

For more information about the CAPRISA 004, trial please visit:

www.caprisa.org

www.fhi.org

www.conrad.org

 

Press Releases

 

CAPRISA Press Release – 20 July 2010

 

Link to FHI Press Release – 20 July 2010

 

Microbicides Trials Network Press Release on CAPRISA 004  - 19 July 2010 

 

AVAC's Press Release on CAPRISA 004 - 19 July 2010

Link to International Partnership for Microbicides Press Statement - 19 July 2010